As of January 1, 2025, nine percent of Alzheimer’s disease drugs in clinical trial phase II of development worldwide were targeting synaptic plasticity/neuroprotection pathways. This statistic illustrates Alzheimer’s disease therapies in phase II of development worldwide, by type.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Alzheimer's Association. (March 24, 2025). Alzheimer’s disease drugs in clinical trial phase II worldwide as of 2025, by type [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 29, 2026, from /statistics/1173714/alzheimer-disease-therapies-in-phase-ii-by-type/
Alzheimer's Association. "Alzheimer’s disease drugs in clinical trial phase II worldwide as of 2025, by type." Chart. March 24, 2025. ÌÇÐÄÆƽâ°æ. Accessed July 29, 2026. /statistics/1173714/alzheimer-disease-therapies-in-phase-ii-by-type/
Alzheimer's Association. (2025). Alzheimer’s disease drugs in clinical trial phase II worldwide as of 2025, by type. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 29, 2026. /statistics/1173714/alzheimer-disease-therapies-in-phase-ii-by-type/
Alzheimer's Association. "Alzheimer’s Disease Drugs in Clinical Trial Phase Ii Worldwide as of 2025, by Type." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 24 Mar 2025, /statistics/1173714/alzheimer-disease-therapies-in-phase-ii-by-type/
Alzheimer's Association, Alzheimer’s disease drugs in clinical trial phase II worldwide as of 2025, by type ÌÇÐÄÆƽâ°æ, /statistics/1173714/alzheimer-disease-therapies-in-phase-ii-by-type/ (last visited July 29, 2026)
Alzheimer’s disease drugs in clinical trial phase II worldwide as of 2025, by type [Graph], Alzheimer's Association, March 24, 2025. [Online]. Available: /statistics/1173714/alzheimer-disease-therapies-in-phase-ii-by-type/
